Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

84.05USD
24 Apr 2018
Change (% chg)

$-1.61 (-1.88%)
Prev Close
$85.66
Open
$86.48
Day's High
$86.73
Day's Low
$82.95
Volume
95,343
Avg. Vol
209,528
52-wk High
$89.26
52-wk Low
$45.20

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $3,409.16
Shares Outstanding(Mil.): 48.39
Dividend: --
Yield (%): --

Financials

  AGIO.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -6.31 -- --
ROI: -46.41 1.58 14.38
ROE: -67.30 2.41 16.07

BRIEF-Agios Says First Patient Dosed In Lymphoma Study

* AGIOS ANNOUNCES FIRST PATIENT DOSED WITH MAT2A INHIBITOR AG-270 IN PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH AN MTAP DELETION Source text for Eikon: Further company coverage:

19 Mar 2018

BRIEF-Agios Reports Qtrly Loss Per Share $1.81

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

14 Feb 2018

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video

22 Jan 2018

UPDATE 3-Celgene to buy Juno for $9 bln to boost cancer pipeline

* Juno's CAR-T drug could rake in $3 bln worldwide in peak sales (Adds background and analyst quote, updates share price)

22 Jan 2018

Agios sizes up funding needs

Jan 19 (IFR) - Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year.

19 Jan 2018

BRIEF-Agios prices offering of 7.09 mln shares at $67 per share

* AGIOS ANNOUNCES PRICING OF $475 MILLION PUBLIC OFFERING OF COMMON STOCK

19 Jan 2018

BRIEF-Agios Announces Proposed Offering Of Common Stock

* SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING

17 Jan 2018

BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value

* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE

08 Jan 2018

BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib

* AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION

26 Dec 2017

BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug

* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION

11 Dec 2017

Competitors

Earnings vs. Estimates